Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis -- Ignore unavailable to you. Want to Upgrade?

To: jad who wrote (1398)	2/16/1998 4:06:00 PM
From: David Wise	Read Replies (1) \| Respond to of 1693

Glad to see there's some action on Quidel thread. I've owned this stock for over a year at $6.00. That patent infringement lawsuit hurt the most. Profits would be great if didn't have to pay royalties to them after the settlement. But I've been wondering if Quidel has a plan to eliminate the payments. Think about this - they have a new pregnancy test kit; they have or are working on new tests for strep and other stuff. All they have to do is substitute sales of the old lines with their new patents and they should reduce or eliminate royalty payments. Of course what's helping now is the revenue increase and new revenue sources via sales contracts. But they're paying a percentage of this revenue to that other company. I hope that as they patent new products to replace the ones that require royalty payments we'll also see margins go up. Anyone else think this could happen?